A Phase Ib/II clinical trial of Venetoclax combined with HMAs and Magrolimab, which is a new anti-human CD47 monoclonal antibody, showed promising results in the treatment of R/R AML and de novo AML, but the trial investigating this combination was limited by futility [42, 46]. This evidence concerns the gene CD47 and acute myeloid leukemia.